Cardinal Health Stock News

Cardinal Health gained nearly 74% year to date, and it has the potential to keep climbing. Loews doesn't own the most exciting portfolio of businesses, but the conglomerate has been steadily gaining over the past 12 months.

Cardinal Health, Inc. ( CAH ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Matt Sims - Vice President of Investor Relations Aaron Alt - Chief Financial Officer Conference Call Participants Kevin Caliendo - UBS Investment Bank, Research Division Presentation Kevin Caliendo UBS Investment Bank, Research Division Good morning, everybody. Thanks for joini...

Cardinal Health (CAH) is evolving into a specialty-focused healthcare leader, leveraging acquisitions and managed services for higher profitability and efficiency. CAH's financials show strong gross profit and net income growth, with operational leverage and robust free cash flow supporting ongoing investments and shareholder returns. Despite solid fundamentals, CAH trades at significant valuat...

Grants are a part of $5 million commitment from Cardinal Health Foundation and awarded by the National Association of Free & Charitable Clinics Grants are a part of $5 million commitment from Cardinal Health Foundation and awarded by the National Association of Free & Charitable Clinics

DUBLIN, Ohio , Nov. 4, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved its quarterly dividend of $0.5107 per share, out of the Company's capital surplus. The dividend will be payable on January 15, 2026 to shareholders of record at the close of business on January 2, 2026.

Adds the country's leading urology MSO with over 750 providers to Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance and brings Cardinal Health's MSO platforms to ~3,000 providers in 32 states DUBLIN, Ohio , Nov. 3, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has completed its acquisition of Solaris Health, the country's leading urology M...

The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed SPY in 2025, with a 6.27% YTD gain versus SPY's 17.8%. Despite overall underperformance, select Aristocrats like CAT, CAH, CHRW, and IBM have delivered strong double-digit returns this year. Dividend growth for the Aristocrats in 2025 averages 5.27%, with most constituents raising payouts, though growth may not exceed 2024...

The healthcare services specialist delivered a beat-and-raise quarter that morning. It posted some strong growth numbers in key fundamentals.